中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Pathological diagnosis of cholestatic liver disease

DOI: 10.12449/JCH240605
More Information
  • Corresponding author: ZHANG Jiping, zjp-zhang@163.com(ORCID: 0009-0000-4878-4607)
  • Received Date: 2024-04-02
  • Accepted Date: 2024-05-14
  • Published Date: 2024-06-25
  • Cholestatic liver disease (CLD) is a group of liver diseases caused by various reasons, such as abnormal bile metabolism, blocked outflow, and bile duct injury, and the major causes of CLD include drugs, poisons, immunity, genetics, obstruction, infection, and tumor. Cholestasis is a common pathological change in CLD; however, the site, histopathology, and ultrastructure of cholestasis due to different etiologies are relatively specific. According to the etiology, this article elaborates on the pathological characteristics of CLD such as autoimmune cholangitis, inherited metabolic liver disease, and large bile duct disease and introduces the differential diagnosis of other types of CLD, in order to improve the understanding of CLD pathology and facilitate accurate diagnosis and treatment.

     

  • [1]
    JOHNSON CA, GISSEN P, SERGI C. Molecular pathology and genetics of congenital hepatorenal fibrocystic syndromes[J]. J Med Genet, 2003, 40( 5): 311- 319. DOI: 10.1136/jmg.40.5.311.
    [2]
    ESTRADAS J, PASCUAL-RAMOS V, MARTÍNEZ B, et al. Autoimmune hepatitis with giant-cell transformation[J]. Ann Hepatol, 2009, 8( 1): 68- 70.
    [3]
    SARCOGNATO S, SACCHI D, GRILLO F, et al. Autoimmune biliary diseases: Primary biliary cholangitis and primary sclerosing cholangitis[J]. Pathologica, 2021, 113( 3): 170- 184. DOI: 10.32074/1591-951X-245.
    [4]
    ZEN Y, HUBSCHER SG, NAKANUMA Y. Bile duct diseases. BurtAD, FerrellLD, HübscherSG, eds. MacSween’s pathology of the liver[M]. 7th ed. Philadelphia, PA: Elsevier, 2018: 515.
    [5]
    TAKAHASHI T, MIURA T, NAKAMURA J, et al. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis[J]. Hepatology, 2012, 55( 3): 846- 855. DOI: 10.1002/hep.24757.
    [6]
    CAREY EJ, ALI AH, LINDOR KD. Primary biliary cirrhosis[J]. Lancet, 2015, 386: 1565- 1575. DOI: 10.1016/S0140-6736(15)00154-3.
    [7]
    KARLSEN TH, FOLSERAAS T, THORBURN D, et al. Primary sclerosing cholangitis-a comprehensive review[J]. J Hepatol, 2017, 67( 6): 1298- 1323. DOI: 10.1016/j.jhep.2017.07.022.
    [8]
    HIRSCHFIELD GM, KARLSEN TH, LINDOR KD, et al. Primary sclerosing cholangitis[J]. Lancet, 2013, 382( 9904): 1587- 1599. DOI: 10.1016/S0140-6736(13)60096-3.
    [9]
    PORTMANN B, ZEN Y. Inflammatory disease of the bile ducts-cholangiopathies: Liver biopsy challenge and clinicopathological correlation[J]. Histopathology, 2012, 60( 2): 236- 248. DOI: 10.1111/j.1365-2559.2011.03853.x.
    [10]
    COLLING R, VERRILL C, FRYER E, et al. Bile duct basement membrane thickening in primary sclerosing cholangitis[J]. Histopathology, 2016, 68( 6): 819- 824. DOI: 10.1111/his.12857.
    [11]
    FIEL MI, SIMA HR, AZARIAN A, et al. A morphometric study of the hepatic arterioles in end-stage primary sclerosing cholangitis[J]. Virchows Arch, 2015, 466( 2): 143- 149. DOI: 10.1007/s00428-014-1680-9.
    [12]
    CARRASCO-AVINO G, SCHIANO TD, WARD SC, et al. Primary sclerosing cholangitis: Detailed histologic assessment and integration using bioinformatics highlights arterial fibrointimal hyperplasia as a novel feature[J]. Am J Clin Pathol, 2015, 143( 4): 505- 513. DOI: 10.1309/AJCPVKFVIPRBXQR2.
    [13]
    NAKAZAWA T, NAITOH I, HAYASHI K, et al. Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification[J]. J Gastroenterol, 2012, 47( 1): 79- 87. DOI: 10.1007/s00535-011-0465-z.
    [14]
    ZHANG JP, HOU XT, YIN ZC, et al. Gilbert syndrome: Clinicopathological and genetic analyses of 29 cases[J]. Chin J Diagn Pathol, 2018, 25( 2): 85- 89. DOI: 10.3969/j.issn.1007-8096.2018.02.002.

    张继平, 侯晓涛, 尹自长, 等. Gilbert综合征29例临床病理及基因分析[J]. 诊断病理学杂志, 2018, 25( 2): 85- 89. DOI: 10.3969/j.issn.1007-8096.2018.02.002.
    [15]
    ATAOLLAHI M, DEHGHANI SM, ANBARDAR MH, et al. Liver histologic changes in children with type 1 of Crigler-Najjar syndrome[J]. Arkh Patol, 2021, 83( 5): 27- 30. DOI: 10.17116/patol20218305127.
    [16]
    FATA CR, GILLIS LA, PACHECO MC. Liver fibrosis associated with crigler-najjar syndrome in a compound heterozygote: A case report[J]. Pediatr Dev Pathol, 2017, 20( 6): 522- 525. DOI: 10.1177/1093526617697059.
    [17]
    WU ZB. Ultramicro-pathological diagnostics[M]. Shanghai: Shanghai Scientific& Technical Publishers, 2003.

    武忠弼. 超微病理诊断学[M]. 上海: 上海科学技术出版社, 2003.
    [18]
    LI LT, WANG JS. Advances in the study of progressive familial intrahepatic cholestasis[J]. Infect Dis Inf, 2019, 32( 2): 162- 165. DOI: 10.3969/j.issn.1007-8134.2019.02.017.

    李丽婷, 王建设. 进行性家族性肝内胆汁淤积症研究进展[J]. 传染病信息, 2019, 32( 2): 162- 165. DOI: 10.3969/j.issn.1007-8134.2019.02.017.
    [19]
    WENG YH, XIONG QF, LIU DX, et al. Clinical and pathological features of progressive familial intrahepatic cholestasis type 3[J]. J Clin Hepatol, 2022, 38( 1): 154- 159. DOI: 10.3969/j.issn.1001-5256.2022.01.024.

    翁宇航, 熊清芳, 刘杜先, 等. 进行性家族性肝内胆汁淤积症3型临床病理特征分析[J]. 临床肝胆病杂志, 2022, 38( 1): 154- 159. DOI: 10.3969/j.issn.1001-5256.2022.01.024.
    [20]
    QIU YL, GONG JY, FENG JY, et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low γ-glutamyltransferase cholestasis[J]. Hepatology, 2017, 65( 5): 1655- 1669. DOI: 10.1002/hep.29020.
    [21]
    GOMEZ-OSPINA N, POTTER CJ, XIAO R, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis[J]. Nat Commun, 2016, 7: 10713. DOI: 10.1038/ncomms10713.
    [22]
    HALAWI A, IBRAHIM N, BITAR R. Triggers of benign recurrent intrahepatic cholestasis and its pathophysiology: A review of literature[J]. Acta Gastroenterol Belg, 2021, 84( 3): 477- 486. DOI: 10.51821/84.3.013.
    [23]
    GUINDI M. Wilson disease[J]. Semin Diagn Pathol, 2019, 36( 6): 415- 422. DOI: 10.1053/j.semdp.2019.07.008.
    [24]
    FANNI D, GUIDO M, GEROSA C, et al. Liver changes in Wilson’s disease: The full spectrum. A report of 127 biopsies from 43 patients[J]. Eur Rev Med Pharmacol Sci, 2021, 25( 12): 4336- 4344. DOI: 10.26355/eurrev_202106_26142.
    [25]
    ZHAO XY, HE ZY, LIU LW, et al. Comparative study of pathological characteristics of 45 patients with primary and secondary hemochromatosis[J]. Infect Dis Inf, 2019, 32( 2): 127- 131. DOI: 10.3969/j.issn.1007-8134.2019.02.007.

    赵新颜, 何志颖, 刘立伟, 等. 45例原发性与继发性血色病临床病理特点对比研究[J]. 传染病信息, 2019, 32( 2): 127- 131. DOI: 10.3969/j.issn.1007-8134.2019.02.007.
    [26]
    MIYAMOTO R, JUN SD, OTA K, et al. Neonatal intrahepatic cholestasis caused by citrin deficiency with no hepatic steatosis: A case report[J]. BMC Pediatr, 2021, 21( 1): 237. DOI: 10.1186/s12887-021-02717-w.
    [27]
    ZHANG JP, CHENG YB, ZHOU XJ, et al. Neonatal intrahepatic cholestasis caused by citrin deficiency: A clinicopathological analysis of two cases[J]. Chin J Diagn Pathol, 2018, 25( 4): 261- 265. DOI: 10.3969/j.issn.1007-8096.2018.04.006.

    张继平, 程艳波, 周晓军, 等. Citrin缺陷导致的新生儿肝内胆汁淤积症2例临床病理观察[J]. 诊断病理学杂志, 2018, 25( 4): 261- 265. DOI: 10.3969/j.issn.1007-8096.2018.04.006.
    [28]
    FABRIS L, MILANI C, FIOROTTO R, et al. Dysregulation of the Scribble/YAP/β-catenin axis sustains the fibroinflammatory response in a PKHD1-/- mouse model of congenital hepatic fibrosis[J]. FASEB J, 2022, 36( 6): e22364. DOI: 10.1096/fj.202101924R.
    [29]
    SAXENA R. Practical hepatic pathology: A diagnostic approach[M]. 2nd Ed. Philadelphia: Elsevier, 2018.
    [30]
    DESMET VJ. Congenital diseases of intrahepatic bile ducts: Variations on the theme“ductal plate malformation”[J]. Hepatology, 1992, 16( 4): 1069- 1083. DOI: 10.1002/hep.1840160434.
    [31]
    CHEN IY, WHITNEY-MILLER CL, LIAO XY. Congenital hepatic fibrosis and its mimics: A clinicopathologic study of 19 cases at a single institution[J]. Diagn Pathol, 2021, 16( 1): 81. DOI: 10.1186/s13000-021-01142-y.
    [32]
    GILBERT MA, BAUER RC, RAJAGOPALAN R, et al. Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification[J]. Hum Mutat, 2019, 40( 12): 2197- 2220. DOI: 10.1002/humu.23879.
    [33]
    WU LN, SUN LY, ZHU ZJ, et al. Clinical and histological characteristics of patients with Alagille syndrome[J]. Chin Hepatol, 2023, 28( 3): 351- 354, 363. DOI: 10.14000/j.cnki.issn.1008-1704.2023.03.018.

    武丽娜, 孙丽莹, 朱志军, 等. Alagille综合征的临床及病理特征分析[J]. 肝脏, 2023, 28( 3): 351- 354, 363. DOI: 10.14000/j.cnki.issn.1008-1704.2023.03.018.
    [34]
    CASANOVA-GONZÁLEZ MJ, TRAPERO-MARUGÁN M, JONES EA, et al. Liver disease and erythropoietic protoporphyria: A concise review[J]. World J Gastroenterol, 2010, 16( 36): 4526- 4531. DOI: 10.3748/wjg.v16.i36.4526.
    [35]
    ANSTEY AV, HIFT RJ. Liver disease in erythropoietic protoporphyria: Insights and implications for management[J]. Gut, 2007, 56( 7): 1009- 1018. DOI: 10.1136/gut.2006.097576.
    [36]
    MACDONALD DM, GERMAIN D, PERROT H. The histopathology and ultrastructure of liver disease in erythropoietic protoporphyria[J]. Br J Dermatol, 1981, 104( 1): 7- 17. DOI: 10.1111/j.1365-2133.1981.tb01705.x.
    [37]
    VIJ M, RELA M. Biliary atresia: Pathology, etiology and pathogenesis[J]. Future Sci OA, 2020, 6( 5): FSO466. DOI: 10.2144/fsoa-2019-0153.
  • Relative Articles

    [1]Xiaodong TENG. Value of biopsy in evaluating the pathological progression of autoimmune hepatitis/pancreatitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1073-1075. doi: 10.12449/JCH240601
    [2]Wenjun YANG. Pathological diagnosis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1082-1087. doi: 10.12449/JCH240603
    [3]Bin WANG. Pathological diagnosis of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2024, 40(6): 1076-1081. doi: 10.12449/JCH240602
    [4]Qiupeng WANG, Meifu GAN. Pathological diagnosis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1088-1092. doi: 10.12449/JCH240604
    [5]Ke SUN. Pathological diagnosis of autoimmune pancreatitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1100-1106. doi: 10.12449/JCH240606
    [6]Yu ZHANG, Yongfeng YANG. Thinking of the pathological diagnosis of unexplained liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(3): 498-503. doi: 10.3969/j.issn.1001-5256.2023.03.003
    [7]Mengmeng ZHANG, Yao MENG, Xinyan ZHAO. Differential pathological diagnosis of liver tissue with normal appearance[J]. Journal of Clinical Hepatology, 2023, 39(3): 517-522. doi: 10.3969/j.issn.1001-5256.2023.03.006
    [8]Xinhang SONG, Juanhan YU, Zhaoping CHENG, Chen SHAO, Baocheng DENG. Pathological staging systems of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(3): 653-655. doi: 10.3969/j.issn.1001-5256.2022.03.033
    [9]Yu YueCheng, Chen ChengWei. Current status and research interests of the diagnosis and treatment of cholestatic liver disease[J]. Journal of Clinical Hepatology, 2019, 35(2): 241-246. doi: 10.3969/j.issn.1001-5256.2019.02.001
    [10]Liu Meng, Yang XuanZi, Yu LeCheng. Current status of the pathogenesis, diagnosis, and treatment of drug-induced cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 252-257. doi: 10.3969/j.issn.1001-5256.2019.02.003
    [11]Jiao DeChao, Lei QinYu, Han XinWei, Li ZongMing, Bi YongHua, Zhang QuanHui. Clinical value of ultra-thin electronic flexible endoscopy combined with intraluminal ultrasound in assisting percutaneous transhepatic biliary stricture biopsy[J]. Journal of Clinical Hepatology, 2019, 35(12): 2744-2747. doi: 10.3969/j.issn.1001-5256.2019.12.021
    [12]Gu TianYi, Lu LunGen. Rationality of medication based on the “ascending” pathophysiology of cholestatic liver disease[J]. Journal of Clinical Hepatology, 2019, 35(2): 266-269. doi: 10.3969/j.issn.1001-5256.2019.02.006
    [13]Liu DuXian, Liu LanXia, Yang YongFeng. Clinical and pathological features of cholestatic liver injury[J]. Journal of Clinical Hepatology, 2018, 34(11): 2283-2288. doi: 10.3969/j.issn.1001-5256.2018.11.004
    [14]Jiang LiLin, Shen JianBo, Tang Hong, Lu ZhongHua. Pathological differential diagnosis of inflammatory liver injury[J]. Journal of Clinical Hepatology, 2018, 34(11): 2278-2282. doi: 10.3969/j.issn.1001-5256.2018.11.003
    [15]Luo WenPing, Ma Hong, Zhao XinYan. Pathological features of hepatic vascular diseases and key points in differential diagnosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2289-2294. doi: 10.3969/j.issn.1001-5256.2018.11.005
    [16]Wu DongBo, Chen EnQiang, Bai Lang, Tang Hong. Liver biopsy and related techniques in pathological diagnosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2295-2299. doi: 10.3969/j.issn.1001-5256.2018.11.006
    [17]Sun FengXia, Sui JingLi, Li Pan, Wang Man, Wu Fang, Li XiaoLing. Biochemical parameters in diagnosis of cholestatic liver disease[J]. Journal of Clinical Hepatology, 2016, 32(8): 1488-1490. doi: 10.3969/j.issn.1001-5256.2016.08.011
    [18]Chinese Society of Liver Cancer, Chinese Anti-Cancer Association, Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Pathology, Chinese Anti-Cancer Association, Digestive Disease Group, Chinese Society of Pathology, Chinese Medical Association, epatic Surgery Group, Chinese Society of Surgery, Chinese Medical Association, Chinese Society of Clinical Oncology, Chinese Anti-Cancer Association, Chinese Pathological Group of Hepatobiliary Tumor and Liver Transplantation. Evidence-based practice guidelines for the standardized pathological diagnosis of primary liver cancer in China( 2015 update)[J]. Journal of Clinical Hepatology, 2015, 31(6): 833-839. doi: 10.3969/j.issn.1001-5256.2015.06.004
    [19]Ni Wei, Shi WeiQun. Clinical diagnosis and liver biopsy diagnosis of 97 cases with chronic HBV infection[J]. Journal of Clinical Hepatology, 2011, 27(6): 623-624+637.
    [20]Zhu QiRong, Wang JianShe. Differential diagnosis of infantile cholestasis[J]. Journal of Clinical Hepatology, 2011, 27(7): 679-681+693.
  • Cited by

    Periodical cited type(2)

    1. 余思邈,王伽伯,肖小河,王睿林. 慢性胆汁淤积性肝病基础上发生药物性肝损伤的新见解与展望. 临床肝胆病杂志. 2025(02): 365-369 . 本站查看
    2. 高雅,唐子轩,郭凯,曹后康,张可锋. ANIT诱导胆汁淤积模型病变与恢复研究. 华夏医学. 2024(06): 25-32 .

    Other cited types(0)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 32.7 %FULLTEXT: 32.7 %META: 54.4 %META: 54.4 %PDF: 12.8 %PDF: 12.8 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.1 %其他: 7.1 %其他: 0.3 %其他: 0.3 %Canton: 0.1 %Canton: 0.1 %China: 0.3 %China: 0.3 %Russian Federation: 0.2 %Russian Federation: 0.2 %Tiruchi: 0.1 %Tiruchi: 0.1 %上海: 4.3 %上海: 4.3 %上饶: 0.1 %上饶: 0.1 %东京都: 0.1 %东京都: 0.1 %东莞: 0.1 %东莞: 0.1 %临汾: 0.1 %临汾: 0.1 %佛山: 0.1 %佛山: 0.1 %佳木斯: 0.2 %佳木斯: 0.2 %保定: 0.1 %保定: 0.1 %信阳: 0.1 %信阳: 0.1 %兰州: 0.2 %兰州: 0.2 %内江: 0.2 %内江: 0.2 %北京: 5.1 %北京: 5.1 %南京: 2.4 %南京: 2.4 %南宁: 0.1 %南宁: 0.1 %南昌: 1.8 %南昌: 1.8 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %厦门: 0.2 %厦门: 0.2 %吉隆坡: 0.1 %吉隆坡: 0.1 %咸宁: 0.1 %咸宁: 0.1 %咸阳: 0.1 %咸阳: 0.1 %哈尔滨: 0.5 %哈尔滨: 0.5 %哥伦布: 0.1 %哥伦布: 0.1 %哥印拜陀: 0.3 %哥印拜陀: 0.3 %喀什: 0.1 %喀什: 0.1 %天津: 0.6 %天津: 0.6 %太原: 0.1 %太原: 0.1 %娄底: 0.2 %娄底: 0.2 %孝感: 0.2 %孝感: 0.2 %孟买: 0.1 %孟买: 0.1 %宁波: 0.1 %宁波: 0.1 %安康: 0.2 %安康: 0.2 %宜宾: 0.2 %宜宾: 0.2 %宜春: 0.2 %宜春: 0.2 %宣城: 0.2 %宣城: 0.2 %山景城: 0.1 %山景城: 0.1 %常州: 0.3 %常州: 0.3 %常德: 0.2 %常德: 0.2 %广州: 2.3 %广州: 2.3 %张家口: 2.2 %张家口: 2.2 %徐州: 0.1 %徐州: 0.1 %悉尼: 0.1 %悉尼: 0.1 %成都: 0.9 %成都: 0.9 %扬州: 0.5 %扬州: 0.5 %承德: 0.1 %承德: 0.1 %抚顺: 0.2 %抚顺: 0.2 %新乡: 0.1 %新乡: 0.1 %新加坡: 0.1 %新加坡: 0.1 %无锡: 0.1 %无锡: 0.1 %日照: 0.1 %日照: 0.1 %昆明: 1.6 %昆明: 1.6 %朝阳: 0.3 %朝阳: 0.3 %杭州: 2.3 %杭州: 2.3 %武汉: 0.4 %武汉: 0.4 %氹仔: 0.1 %氹仔: 0.1 %汕头: 0.1 %汕头: 0.1 %沈阳: 0.4 %沈阳: 0.4 %泸州: 0.1 %泸州: 0.1 %济南: 1.0 %济南: 1.0 %海得拉巴: 0.2 %海得拉巴: 0.2 %深圳: 0.4 %深圳: 0.4 %温州: 0.2 %温州: 0.2 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.3 %漯河: 0.3 %漳州: 0.1 %漳州: 0.1 %焦作: 0.1 %焦作: 0.1 %盐城: 0.1 %盐城: 0.1 %眉山: 0.3 %眉山: 0.3 %石家庄: 0.5 %石家庄: 0.5 %福州: 0.1 %福州: 0.1 %科泽科德: 0.1 %科泽科德: 0.1 %穆列塔: 0.1 %穆列塔: 0.1 %纽约: 0.4 %纽约: 0.4 %绍兴: 0.3 %绍兴: 0.3 %芒廷维尤: 28.2 %芒廷维尤: 28.2 %芜湖: 0.1 %芜湖: 0.1 %芝加哥: 1.7 %芝加哥: 1.7 %苏州: 0.3 %苏州: 0.3 %荆州: 0.2 %荆州: 0.2 %莫斯科: 0.4 %莫斯科: 0.4 %葵涌: 0.1 %葵涌: 0.1 %衡水: 0.2 %衡水: 0.2 %西双版纳: 0.1 %西双版纳: 0.1 %西宁: 10.9 %西宁: 10.9 %西安: 0.3 %西安: 0.3 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 1.0 %贵阳: 1.0 %运城: 0.7 %运城: 0.7 %遵义: 0.1 %遵义: 0.1 %郑州: 1.5 %郑州: 1.5 %重庆: 0.9 %重庆: 0.9 %铁岭: 0.2 %铁岭: 0.2 %银川: 0.2 %银川: 0.2 %镇江: 0.1 %镇江: 0.1 %长春: 6.8 %长春: 6.8 %长沙: 2.0 %长沙: 2.0 %阿什本: 0.1 %阿什本: 0.1 %阿姆斯特丹: 0.1 %阿姆斯特丹: 0.1 %青岛: 0.5 %青岛: 0.5 %马德里: 0.1 %马德里: 0.1 %其他其他CantonChinaRussian FederationTiruchi上海上饶东京都东莞临汾佛山佳木斯保定信阳兰州内江北京南京南宁南昌卡纳塔克厦门吉隆坡咸宁咸阳哈尔滨哥伦布哥印拜陀喀什天津太原娄底孝感孟买宁波安康宜宾宜春宣城山景城常州常德广州张家口徐州悉尼成都扬州承德抚顺新乡新加坡无锡日照昆明朝阳杭州武汉氹仔汕头沈阳泸州济南海得拉巴深圳温州湘潭漯河漳州焦作盐城眉山石家庄福州科泽科德穆列塔纽约绍兴芒廷维尤芜湖芝加哥苏州荆州莫斯科葵涌衡水西双版纳西宁西安诺沃克贵阳运城遵义郑州重庆铁岭银川镇江长春长沙阿什本阿姆斯特丹青岛马德里

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(6)

    Article Metrics

    Article views (554) PDF downloads(128) Cited by(2)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return